Avalon Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avalon Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,970	Closed	-$743K	–	83
2016 Q4	$743K	Sell	8,970 -75	-0.8%	-$6.45K	0.57%	52
2016 Q3	$837K	Buy	+9,045	New	+$852K	0.64%	44
2016 Q2	–	Sell	-9,425	Closed	-$777K	–	73
2016 Q1	$777K	Buy	+9,425	New	+$767K	0.62%	41

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Avalon Capital Management's BMRN Position: Q1 2017 in Review

Avalon Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 8,970 shares — an estimated $743K sold.

Avalon Capital Management first reported a position in BMRN in Q1 2016 and held it in 3 quarters. The position peaked at $837K in Q3 2016. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Avalon Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Avalon Capital Management sold 8,970 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $743K.
Avalon Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Avalon Capital Management's BioMarin Pharmaceuticals position peaked at $837K in Q3 2016.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Avalon Capital Management's 13F filing for Q1 2017, filed 26 Apr 2017.